-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice.
gallbladder; ileum; intestine; signal transduction THE APICAL SODIUM-DEPENDENT bile acid transporter, ASBT (slc10a2), plays a critical role in the enterohepatic circulation of bile salts (13) . ASBT mediates sodium-dependent bile acid transport in ileal enterocytes, renal proximal convoluted tubule cells, and cholangiocytes. ASBT expression is relevant for bile acid, cholesterol, glucose, and lipid homeostasis (12) . Genetic defects in ASBT expression are associated with congenital diarrhea, which can be mimicked in a mouse knockout model (14, 41) . Pharmacological inhibition of its function leads to intestinal wasting of bile acid and commensurate conversion of cholesterol into bile acids with a significant impact on cholesterol homeostasis (22, 42) . Inhibition of ASBT function can also ameliorate hyperglycemia in a mouse model (8) . Ileal ASBT expression is reduced in patients with hypertriglyceridemia (15) . Alterations in ASBT expression may influence a variety of disease processes and conditions including diarrhea, cholestasis, and necrotizing enterocolitis. ASBT is repressed in the setting of intestinal inflammation, which may exacerbate diarrheal symptoms in Crohn disease (28) . Maladaptive upregulation of ASBT expression may be a generalized problem in cholestasis and a more specific pathogenesis of the cholestasis associated with defects in the ATP8B1 gene (Byler disease) (2, 23) . Necrotizing enterocolitis in a mouse model is attenuated when ASBT is inhibited or genetically deleted (21) . In light of the findings, ASBT has become an interesting target for new pharmacological therapies including treatment of constipation, primary biliary cirrhosis, and Alagille syndrome (10) (http://clinicaltrials.gov/ last accessed 09. 28.13) .
Given its importance in health and disease, the expression of ASBT is tightly controlled at varied levels including transcriptional and posttranscriptional regulation. ASBT has been shown to be transcriptionally activated by the HNF-1a, c-Jun, the glucocorticoid receptor, the peroxisome proliferator-activated receptor, the vitamin D receptor and the caudal-type homeobox protein (4, 9, 28, 29, 35, 45) . ASBT expression is regulated posttranscriptionally including changes in ASBT mRNA stability mediated by the RNA binding proteins Hu antigen R and tristetraprolin (7) . ASBT targeting to the plasma membrane is reduced by activation of protein kinase c zeta (44) . The ubiquitin-proteasome pathway mediates regulated degradation of ASBT (52) . ASBT has been recently described as a regulatory target of the enterokine, fibroblast growth factor-19 (FGF-19) (47) .
FGF-19 (mouse ortholog FGF-15) is an atypical member of the family of FGFs, which were initially characterized by their ability to stimulate fibroblast proliferation through FGF receptors (27) . FGF-19 is not tightly bound by extracellular matrix and thus can act as an endocrine, paracrine, or autocrine factor. FGF-19 is synthesized in enterocytes and cholangiocytes and mediates its effects through the cell surface proteins FGFR4 and ␤-Klotho (26, 54) . Ileal FGF-19 regulates hepatocytebased bile acid metabolism (25) . A wide spectrum of targets and homeostatic processes have been discovered to be influenced by . ␤-Klotho knockout mice have enhanced hepatic bile acid secretion, yet unlike canalicular bile acid transporter-overexpressing mice, commensurate downregulation of ASBT expression in response to the enhanced delivery of bile acids to the ileum is not observed (18, 26) . This suggests that FGF-19 is a physiological regulator of ASBT expression. FGF-19 transcription is activated by bile acids via the farnesoid X-receptor (FXR). As an autocrine factor, FGF-19 may repress ASBT expression, providing an immediate feedback loop controlling bile acid pool size. Enhanced delivery of bile acids to the ileum increases FGF-19, which through an autocrine loop represses ASBT, leading to intestinal wasting of bile acids.
ASBT expression is negatively regulated by a number of mechanisms. One pathway involves FXR-mediated activation of the short heterodimer partner and subsequent inactivation of the liver receptor homolog-1 (retinoic acid receptor in humans) (5, 39) . Since the liver receptor homolog-1 is an activator of ASBT, the net effect is an indirect negative feedback regulation of ASBT by bile acids. A second inhibitory pathway involves the activator protein-1 (AP-1), c-Fos. This pathway is active in mediating response to inflammatory cytokines. The ASBT promoter contains two distinct AP-1 binding sites. The upstream site, uAP-1, binds a c-Jun homodimer that activates the promoter. In contrast, the downstream site, dAP-1, binds a c-Fos/c-Jun heterodimer leading to repression of ASBT transcription (6) . FGF proteins activate immediate early response genes, like AP-1 (34) . We therefore hypothesized that FGF-19 represses ASBT expression via a signaling pathway involving c-Fos.
MATERIALS AND METHODS

Cell Culture
Human Caco-2 colon epithelial cells (HTB-37, ATCC) were grown in Eagle's minimum essential medium (EMEM) with 20% fetal bovine serum (FBS). Mouse CT-26 cells (CRL-2638, ATCC) were grown in RPMI medium with 10% FBS. Caco-2 cells were chosen for these studies because of their ability to provide accurate in vitro modeling of signal transduction pathways involved in bile acid transporter homeostasis and in response to inflammatory cytokines (16, 38, 44, 46, 47) . CT-26 cells were chose as a mouse intestine cell line that recapitulates relevant signal transduction pathways (20) . Cells treated with PD98059 (Calbiochem, EMD Millipore, Billerica, MA), U0126 (Cell Signaling Technology, Beverly, MA), or recombinant human FGF-19 (R&D Systems, Minneapolis, MN), were supplemented with 0.5% charcoal-treated FBS, minimizing the effect of bile acids found in FBS (19) . Plasmid transfected cells were cultured for 48 h before harvest for reporter gene assays.
Plasmid Constructs
The following constructs were used in these studies. pGL3-hASBT5=/0.6 (ASBT) and pGL3-hASBT5=/0. ]. pGL3-hASBT/0.6 contains nucleotides Ϫ337 to ϩ297 of the human ASBT 5= flanking region linked to a firefly luciferase reporter gene (38) . pGL3-hASBT5=/0.6-dAP1 contains a mutation in dAP-1 that blocks response to c-Fos (38) . The c-foscontaining (pCMV/c-fos) was a generous gift from Dr. Scott Plevy, University of North Carolina, Chapel Hill, NC (4, 6) .
SV40/dAP1 and SV40/ZErO. SV40/dAP1 contains a dAP-1 45-bp fragment downstream of the SV40 promoter in the luciferase reporter plasmid, pGL3-promoter (6) . The control plasmid, SV40/ZErO, contains a nonspecific sequence in the same site (6) .
Silencing RNAs. Silencing RNAs for c-fos (sc-29221), c-jun (sc-29223), JNK1 (sc-29380), and JNK2 (sc-39101) were purchased (Santa Cruz Biotechnology, Santa Cruz, CA).
Transient Transfection and Firefly Luciferase Assay
The 1 ϫ 10 6 confluent cells in 1 ml of serum-free EMEM were transfected with 3 g of promoter/luciferase constructs and 0.1 g of thymidine kinase promoter-driven quantitation control Renilla luciferase (Promega, 
PD98059 and U0126 Dose Response
To examine the effect of MEK1/2 inhibitors on human ASBT promoter activity, Caco-2 cells were treated for 48 h with increasing concentration of PD98059 (0, 10, 25, 50, 75, and 100 M) or U0126 (0, 0.05, 0.1, 0.5, 1, and 5 M). PD98059 is an inhibitor of MEK1, whereas U0126 is a highly selective and potent inhibitor of both MEK1 and MEK2 (17) .
FGF-19 Dose
To examine the effect of FGF-19 on ASBT protein expression, Caco-2 cells were treated with increasing concentrations of recombinant FGF-19 (0, 50, 100, and 150 g/l) for 48 h. For ASBT promoter activity, ASBT, dAP1ASBT(mut), SV40/dAP1, or SV40/ ZErO luciferase constructs were transfected into Caco-2 cells treated with 50 g/l of FGF-19; 50 g/l FGF-19 was chosen to avoid potential nonspecific effects from higher concentrations of FGF-19. Studies in CT-26 cells used the mouse ASBT promoter and 100 g/l of FGF-19.
Preparation of Whole Cell Extracts from Cultured Caco-2 Cells
As previously described (3), whole cell extracts (WCE) were prepared from 1 ϫ 10 6 Caco-2 cells that were suspended in 50 l of RIPA Lysis buffer and 1ϫ Halt Protease and Phosphatase Inhibitor cocktail (Thermo Scientific, Rockford, IL).
Preparation of Total Homogenate, Membrane, Cytoplasmic, and Nuclear Extracts
Total homogenate and membrane proteins were prepared from ileum and gallbladder by modification of a previously described technique (11) . Weighted tissue (ileum and gallbladder) was homogenized 10 times by using an OMNI International homogenizer in 10 volumes of ice-cold homogenization buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl 2, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 20% glycerol and 1ϫ Halt Protease and Phosphatase Inhibitor cocktail). Tissue lysates were centrifuged at 2,400 g for 10 min, pelleting nonhomogenized tissue debris. The supernatant was used as total-homogenate fraction. For analysis of gallbladder each sample was a combination of tissue from the four mice of the same group.
For isolation of a crude membrane fraction from Caco-2 cells, WCE were used in place of total homogenate fraction. Homogenate from tissues or WCE from Caco-2 cells were spun at 30,590 g for 30 min at 4°C. The pellet was resuspended in homogenization buffer and spun at 30,590 g for 30 min. The pellet (crude membrane) was resuspended in buffer (300 mM Mannitol, 10 mM HEPES-KOH buffer, pH 7.5 and 1ϫ Halt Protease and Phosphatase Inhibitor cocktail).
Cytoplasmic and nuclear proteins were prepared from tissues or cultured cells by using the NE-PER kit (Thermo Scientific, Rockford, IL) according to the manufacturer's instructions.
Protein concentrations of all the extracts were determined by using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA).
Western Blotting
Western blotting was performed as previously described (6) . The following antibodies were used for these studies: anti-ASBT (sc-27493), anti-JNK1 (F-3, sc-1648), and anti-JNK2 (N-18, sc-827); antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-c-Jun (60A8) rabbit 9165, anti-phospho-c-Jun (Ser 63) 54B3 rabbit 2361, c-Fos (9F6) rabbit 2250, and anti-phospho-cFos (Ser 32) D82C12 XP rabbit 5348 antibodies were purchased from Cell Signaling Technology (Danvers, MA). As a loading control for plasma membrane proteins, anti-Na ϩ -K ϩ -ATPase (Abcam, Cambridge, MA) antibody was used as a loading control for plasma membrane proteins, anti-␤-actin antibody (Sigma Aldrich, St. Louis, MO) for homogenates or cytoplasmic fractions, and TATA binding protein (Abcam) for nuclear extracts.
Animal Studies
All experiments were approved by the Animal Care and Use Committee of the University of Pittsburgh. Intestinal specific silencing of the c-fos gene was attained by crossing mice harboring a floxed c-fos allele (f/fc-fos) (55) with mice expressing Cre recombinase in the intestine as directed by the villin promoter Tg (Vil-cre) (Jackson Laboratories, Bar Harbor, ME) (36) . Mouse genotyping was performed by Southern blotting as described (55) and/or by PCR of the neomycin cassette in exon 4 of the c-fos gene, with a forward primer 5= GGA TTT GAC TGG AGG TCT GC 3= and a reverse primer neo 5= TTG AAG CGT GCA GAA TGC 3= (450 bp) or a reverse primer c-fos 5= ATG ATG CCG GAA ACA AGA AG 3= (170 bp). Silencing of c-fos in the intestine was confirmed by Western blot analysis of c-Fos and/or phospho-c-Fos in nuclear extracts from appropriate tissues. Four distinct groups of male mice were ultimately studied, wild type (C57BL6J), c-fos int 
FGF-19 ELISA
FGF-19 was measured in the cytoplasmic extracts (20 g) of mouse ileal tissues of group 1 through group 8, as described above. The amount of FGF-19 was quantified from a standard curve, following the assay procedure of a solid-phase sandwich ELISA kit (R&D Systems).
Statistical Analyses
Statistical analyses were performed with In-Stat software (GraphPad Software, San Diego, CA). Unless otherwise stated, means were compared by Tukey-Kramer multiple comparisons test, all values are expressed as mean Ϯ standard deviation, and a value of P Ͻ 0.05 was considered statistically significant.
RESULTS
FGF-19 Treatment Represses ASBT in Caco-2 Cells
Addition of FGF-19 to the media of Caco-2 cells led to a dose-dependent repression of endogenous ASBT protein in WCE (Fig. 1A) . Since 50 g/l of FGF-19 led to significant repression of ASBT, this dose of FGF-19 was used in cell culture throughout the study, unless specifically indicated.
Signal Transduction Pathways Initiated by FGF-19 in Caco-2 Cells
Signal transduction pathways activated by FGF-19 were assessed by Western blot analysis of proteins extracted from cytoplasmic ( Fig. 1B) and nuclear (Fig. 1C) fractions of Caco-2 cells treated with FGF-19. Within 1 h, there was a transient activation of p-ERK1/2, JNK1 and JNK2 without a change in total ERK1/2 (Fig. 1B) . In the nuclear extracts there was similar transient phosphorylation of jun and fos (Fig. 1C) .
Silencing MEK1/2 Pathway Activates ASBT
To assess the effect of inhibiting MEK1/2 pathway on ASBT, promoter analysis was performed in Caco-2 cells transfected with pGL3-hASBT along with the MEK1/2 chemical inhibitors PD98059 or U0126. U0126 was added in doses from 1 to 20 M (49) whereas PD98059 was added in doses from 10 to 100 M (40). A dose-dependent increase in ASBT promoter activity was observed in response to either PD98059 or U0126, suggesting that the MEK/ERK pathway endogenously represses ASBT (Fig. 2A) . U0126 is a more specific and potent inhibitor of the MEK pathway (17) . Therefore, U0126 was used in subsequent studies for the inhibition of MEK1/2. U0126 treatment of Caco-2 cells induced a significant increase in endogenous ASBT protein expression (Fig. 2B , no treatment: 233 Ϯ 60 vs. U0126 treatment: 3,307 Ϯ 166 densitom- 
Antagonistic Effects of JNK1 and JNK2 on ASBT Promoter Activity
Our studies (Fig. 1B) suggest that FGF-19 signals through JNK1 and JNK2. To determine the effects of JNK1 and JNK2 on ASBT promoter activity, Caco-2 cells transfected with pGL3-hASBT were pretreated with the silencing constructs for JNK1 and/or JNK2 in the absence or presence of FGF-19. As previously observed, FGF-19 treatment repressed ASBT promoter activity (Fig. 3) . Silencing JNK1 led to repression of ASBT whereas silencing JNK2 enhanced ASBT promoter activity. The effect of si-JNK1 or si-JNK2 was observed independent of the addition of exogenous FGF-19 (ASBT: 176 Ϯ 35; ϩFGF-19: 68 Ϯ 10; ϩsi-JNK1: 71 Ϯ 8; ϩsi-JNK2: 272 Ϯ 23; ϩsi-JNK1ϩFGF-19: 72 Ϯ 9; ϩsi-JNK2ϩFGF-19: 287 Ϯ 72; n ϭ 9; see Fig. 3 for relevant statistical comparisons). Moreover, when both JNK-1 and JNK2 were silenced, the effect of silencing JNK1 predominated over JNK2 silencing (ϩsi-JNK1ϩsi-JNK2: 71 Ϯ 10, ϩsi-JNK1ϩsi-JNK2ϩFGF-19: 70 Ϯ 7) (Fig. 3) .
Counterregulatory Effects of c-Jun and c-Fos on the ASBT Promoter
Previous studies have shown that c-Jun is an activator whereas c-Fos is an inhibitor of ASBT (4) . To test the hypothesis that FGF-19-mediated repression of ASBT occurs via the AP-1 pathway, c-Jun and c-Fos expression in Caco-2 cells were modulated in presence or absence of FGF-19 (Fig. 4A) . As expected, forced expression of c-Jun activated the ASBT promoter whereas silencing the gene repressed ASBT (ASBT: 143 Ϯ 25; ϩc-jun: 305 Ϯ 43; ϩsi-c-jun: 65 Ϯ 7 RLUs; P Ͻ 0.001 for all comparisons). Conversely, c-Fos overexpression repressed the ASBT promoter whereas silencing it activated ASBT (ASBT: 143 Ϯ 25; ϩc-fos: 12 Ϯ 2; ϩsi-c-fos: 287 Ϯ 31 RLUs; P Ͻ 0.001 for all comparisons). Furthermore, when c-Jun or c-Fos expression was modulated, FGF-19 treatment had no effect on the ASBT promoter unlike the repression typically observed with FGF-19 expression.
Inhibitory Effect of FGF-19 Is Mediated in Part by the Distal AP-1 Element in the ASBT Promoter
The promoter for ASBT contains two distinct AP-1 binding sites. The distal AP-1 cis-element, dAP-1, mediates inflammatory repression of ASBT via interactions with c-Fos (38). The ASBT promoter activity was assessed by use of a luciferase reporter construct. Silencing JNK1 in Caco-2 cells leads to ASBT promoter repression, whereas JNK2 silencing activated ASBT. Moreover, the JNK1 effect predominated when both JNK1 and JNK2 were silenced (P Ͻ 0.001 for the comparisons shown on the figure). When JNK1 and/or JNK2 were silenced there was no effect of FGF-19 treatment. (Fig. 4B) . Site-directed point mutation of the dAP-1 element completely abolished ASBT promoter responses to both c-Fos and FGF-19. Basal promoter activity of the mutant promoter was severalfold greater than the wildtype (ASBT) promoter, presumably owing to blocking of endogenous c-Fos repression that exists in Caco-2 cells [ASBT: 67 Ϯ 10; dAP1ASBT(mut): 269 Ϯ 32 RLUs; P Ͻ 0.001]. Unlike the wild-type ASBT promoter, no change in the activity of the dAP-1 mutant promoter was observed in response to FGF-19 and/or changes in c-Fos expression. The dAP-1 mutant promoter was responsive to changes in c-Jun as would be expected since the uAP-1 (c-Jun responsive) element is unchanged in this construct (data not shown).
The effects of FGF-19 and c-fos on the ASBT promoter was recapitulated in a heterologous construct driven by the SV-40 promoter, which harbors the dAP-1 element (Fig. 4C) . The SV40/dAP-1 promoter activity was reduced by either FGF-19 administration or c-fos transfection and activated by si-c-fos treatment (SV40/dAP-1: 404 Ϯ 32; ϩFGF: 220 Ϯ 23; ϩc-fos: 183 Ϯ 15; ϩsi-c-fos: 530 Ϯ 21 RLUs; n ϭ 9, P Ͻ 0.001 for all comparisons relative to the baseline construct). When c-Fos expression was modulated the effect of FGF-19 was abrogated (ϩc-fosϩFGF: 251 Ϯ 23; ϩsi-c-fosϩFGF: 502 Ϯ 23; P Ͼ 0.05 for si-c-fos vs. si-c-fosϩFGF or ϩc-fos vs. ϩc-fosϩFGF). These findings are analogous to the human ASBT promoter reporter results. In contrast and as expected, SV40/ pZErO, the negative control dAP1 element-containing construct, showed no change in the promoter activity in response to alterations in c-Fos expression or FGF-19 treatment.
FGF-19-Responsive Regulatory Pathways in CT-26 Cells
The pathways identified in Caco-2 cells were tested in the mouse intestinal cell line, CT-26. As with the Caco-2 linederived analyses, the ASBT promoter was repressed in response to FGF-19 and activated by treatment with U0126 or in response to silencing of c-fos. U0126 treatment blocked FGF-19-mediated repression, whereas silencing c-fos diminished but did not completely block the response to FGF-19 (control: 28.7 Ϯ 6.5; ϩ FGF: 1.9 Ϯ 0.5; ϩ U0126: 61.8 Ϯ 16.0; ϩ si c-fos: 117.7 Ϯ 14.0; ϩ U0126 ϩ FGF: 47.4 Ϯ 5.4; ϩ si c-fos ϩ FGF: 92.1 Ϯ 6.7, n ϭ 6, P Ͻ 0.001 for control vs. FGF or U0126 or si c-fos, P Ͻ 0.01 for si c-fos vs. si c-fos ϩ FGF, P Ͼ 0.05 for U0126 vs. U0126 ϩ FGF). the ileum of mice that did not express c-Fos; in contrast, it was nonsignificantly increased in response to FGF-19 (group 4, Fig. 5, A and B) . FGF-19 treatment of the cre cont and c-fos hypo mice led to significant reductions in ASBT (data not shown).
FGF-19 Induced Downregulation of Mouse ASBT in Ileum Is Dependent on c-Fos
The signal transduction pathways identified in vitro were active in vivo. FGF-19 treatment was associated with induction of JNK1 and JNK2 expression and led to enhanced phosphorylation of ERK1/2 in cytoplasmic extracts of ileal tissue (Fig. 5,  C and D) . c-fos was effectively silenced by the cre-lox strategy used in this breeding, as noted by the minimal or absent c-Fos protein detection in the ileum of group 3 and 4 mice (Fig. 5, E  and F) . In wild-type as well as in ileal c-fos knockout mice, FGF-19 treatment activated the phosphorylation of c-Jun in nuclear extracts (Fig. 5, E and F) . Molecular events were assessed in the gallbladder of the same mice. The villin promoter does not direct expression to the gallbladder and thus as such c-Fos was expressed in the gallbladder of c-fos Ϫint mice (Fig. 6C) . The same signal transduction pathways were activated by FGF-19 in the gallbladder and ASBT was repressed in both the wild-type and c-fos Ϫint mice (Fig. 6) .
Similar results to wild-type mice were observed in ileum (not shown) and gallbladder (Fig. 6) 
DISCUSSION
FGF-19 is an enterokine, which regulates a number of biologically important processes (31) . The major focus of most investigations to date has been signaling from the ileum to the liver or gallbladder by FGF-19 in response to bile acids (27, 31) . The present studies support the supposition that FGF-19 may also act in an autocrine fashion, leading to negative feedback regulation of intestinal bile acid transport. Intraperitoneal administration of 400 g/kg of recombinant FGF-19 leads to reproducible and rapid repression of ASBT protein expression in both the ileum and gallbladder. This dosing regimen in these studies is in the range of prior mouse-based experiments and yields tissue concentrations that are in the same order of magnitude of serum concentrations of FGF-19 (30, 34, 50) . The high level of secretion of FGF-19 by the gallbladder raises the possibility of autocrine or paracrine signaling to cholangiocytes, thereby altering expression of apical bile acid transport (56) . Clearly there are complex systems biology issues present in analyzing the effects of perturbations of the enterohepatic circulation of bile acids. The panoply of regulatory mechanisms for bile acid homeostasis ensure tight control of both the size of the bile acid pool and its distribution throughout the body.
FGF-19-mediated repression of ASBT occurs via the receptor complex of FGFR4 and ␤-Klotho signaling via mitogenactivated pathways involving MEK, ERK, JNK, and AP-1 ( Fig. 7) (43) . FGF-19 signals through FGFR4 and ␤-Klotho to phosphorylate and activate ERK1/2 in a MEK1/2 dependent pathway (33) . ERK1/2 phosphorylation was observed in the ileum and gallbladder in response to exogenous FGF-19 administration. Signaling to ASBT was blocked by small molecular inhibitors of MEK1/2. Activated ERK1/2 has the capacity to signal through JNK and also directly via phosphorylation of c-Fos (37, 51) . Expression of JNK1 and JNK2 is enhanced in response to FGF-19. JNK1 typically phosphorylates c-Jun and would be expected to activate ASBT. Silencing JNK1 in these studies led to the predicted reduction in ASBT promoter FGF-19 is also known to repress the expression of cholesterol 7-␣ hydroxylase (CYP7A1), a key enzyme in bile acid biosynthesis (24) . Bile acids exert negative feedback regulation on the transcription of both ASBT and CYP7A1, with the primary mechanism involving FXR mediated activation of the expression of the short heterodimer partner followed by inactivation of permissive transcription factors, like the liver receptor homolog-1 (5, 39) . The exact mechanism of FGF-19-mediated repression of CYP7A1 remains controversial but may be FXR independent and operate through a signal pathway similar to that observed in the intestine and gallbladder involving MEK, ERK, and JNK (24, 32, 48, 53) . FGF-19 treatment leads to enhanced c-Fos expression in the liver but a link of c-Fos to CYP7A1 is not known (34) . In whole animal models and in some cell culture systems it is difficult to dissect out FXR and MAPK signaling pathways, in particular because FGF-19 expression is FXR dependent.
In summary, FGF-19 represses the expression of ASBT in the ileum and gallbladder via a signal transduction pathway involving the cell surface receptors ␤-Klotho and FGF receptor 4 and the signaling molecules MEK1/2, ERK1/2, JNK1, JNK2, and c-Fos. FGF-19 is well described as an enterokine that acts in a paracrine manner. These studies suggest that autocrine effects in enterocytes and cholangiocytes should be considered in assessing the biology of this interesting signaling molecule. A classical mitogen growth factor signaling pathway terminating in c-Fos is operant in the repression of ASBT and should be considered in other effects of FGF-19.
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